Purpose of review Diffuse cystic lung diseases (DCLDs) are a heterogeneous group of disorders with varying pathophysiologic mechanisms that are characterized by the presence of air-filled lung cysts. These cysts are prone to rupture, leading to the development of recurrent spontaneous pneumothoraces. In this article, we review the epidemiology, clinical features, and management DCLD-associated spontaneous pneumothorax, with a focus on lymphangioleiomyomatosis, Birt-Hogg-Dubé syndrome, and pulmonary Langerhans cell histiocytosis.
INTRODUCTION
Diffuse cystic lung diseases (DCLDs) are a heterogeneous group of disorders sharing a common radiographic feature of discrete air-filled cysts on highresolution computed tomography (HRCT) scan of the chest. The differential diagnosis of DCLDs is quite broad (Table 1) and encompasses a wide set of underlying pathophysiologic mechanisms [1 & ]. Although the clinical manifestations vary between the different DCLDs, the vast majority of these diseases share an increased propensity to cause recurrent spontaneous pneumothoraces. In this review, we will provide an overview of the epidemiology, clinical features, and management of spontaneous pneumothoraces in patients with DCLDs.
Lymphangioleiomyomatosis
Lymphangioleiomyomatosis (LAM) is a low-grade metastasizing neoplasm primarily affecting women and is characterized by infiltration of the lung interstitium with abnormal smooth muscle cells [2] . LAM 
PNEUMOTHORAX IN LYMPHANGIOLEIOMYOMATOSIS
55-73% of patients with LAM experience a pneumothorax in their lifetime [4, 5, [12] [13] [14] [15] [16] [17] [18] , with pneumothorax leading to the diagnosis of LAM in approximately 40% of patients [4, 5, 16] . On average, patients experience 2.2 pneumothoraces before the diagnosis of LAM is made (Table 2) [4, 15, 17, [19] [20] [21] 22 & ,23]. Among patients with at least one pneumothorax, 73-85% will have multiple pneumothoraces [13, 15] , with ipsilateral recurrence rates of approximately 70% [15] . Patients with a history of pneumothorax average between 3.5 and 4.4 total pneumothoraces [4, 15] , with over 10% developing more than 10 pneumothoraces [13] . In patients who require lung transplant, posttransplant pneumothorax of native lung occurs in 7-12% of cases [24, 25] .
Patients are usually in their 3rd or 4th decade at the time of their first pneumothorax [15] . Concurrent chylothorax and pneumothorax can occur [26 & ]. The majority (80%) of the pneumothoraces occur at rest or with minimal activity [15] . Patients with larger cyst size on HRCT (>5 mm) [13] and those with a history of smoking [27] are more likely to develop a pneumothorax. Pregnancy may be associated with increased risk of pneumothorax [28] .
Pneumothorax accounts for significant morbidity among patients with LAM. It is the most common reason for unscheduled hospitalization, and patients with recurrent pneumothorax average five pneumothorax-related procedures each [4, 15, 29] . In one study, a pneumothorax-related hospitalization averaged 8 days, resulting in approximately 29 days of total pneumothorax-related hospitalization time per patient and $75 000 in pneumothorax-related cost [15] . Pneumothorax in LAM can occasionally be fatal [16] .
It has been suggested that patients with LAM presenting with a pneumothorax have a more favorable prognosis compared with those presenting with dyspnea [16, 17] . However, earlier diagnosis of the disease may account for the difference in prognosis rather than a true biological effect in these cases.
MANAGEMENT
Some of the management principles regarding pneumothoraces are applicable not only to LAM, but all patients with DCLDs. All patients with DCLDs should be counseled on the symptoms of pneumothorax and advised to seek medical care immediately if those symptoms present. Smoking cessation should be strongly encouraged. Whenever possible, pneumothorax should be managed by clinicians with expertise in addressing pleural complications of DCLDs.
Given the high rates of recurrence, pleurodesis should be performed after the first spontaneous
KEY POINTS
DCLDs are a common cause of spontaneous pneumothorax and can represent approximately 10% of the patients presenting with an apparent primary spontaneous pneumothorax.
Performing a screening high-resolution computed tomography scan for DCLDs in patients presenting with a first episode of spontaneous pneumothorax is costeffective and can help facilitate timely diagnosis and appropriate management of these patients.
Patients with underlying DCLDs and a sentinel pneumothorax have a very high rate of recurrence, if managed conservatively.
Due to the high recurrence rate, pleurodesis should be considered following the initial episode of pneumothorax in patients with DCLDs rather than waiting for a recurrent event.
Prior pleurodesis is not a contraindication to lung transplant.
pneumothorax in patients with LAM rather than waiting for a recurrence.
Pleurodesis, although not perfect, reduces the recurrence risk substantially. In one study, the ipsilateral pneumothorax recurrence rate was 66% if managed conservatively, but this was reduced to 27% with chemical pleurodesis and 32% with surgical pleurodesis [15] . Postpleurodesis pain is a significant concern for patients with LAM; patient preferences regarding early pleurodesis differ markedly from the clinicians and should be taken into account when making decisions about pleurodesis [30] .
It is important to note that although prior pleurodesis can lead to increased risk of bleeding and prolongation of the operative time, it does not impact outcomes such as mortality, or length of hospital stay [15, 25] , and is not a contraindication for lung transplant [31] .
Recently, the mTOR inhibitor sirolimus was shown to stabilize lung function decline and improve quality of life among patients with LAM [32] . Sirolimus is now considered the first-line treatment option for qualifying LAM patients [9 & ]; however, the impact of sirolimus on future risk of pneumothoraces needs to be studied.
Pulmonary Langerhans cell histiocytosis
Pulmonary Langerhans cell histiocytosis (PLCH) is a rare, smoking-associated, progressive DCLD, predominantly affecting young-to-middle-aged [33] .
The central lesion in PLCH is the bronchiolocentric accumulation of Langerhans cells activated by exposure to cigarette smoke. These activated Langerhans cells attract other immune cells leading to destruction of bronchiolar walls with airspace enlargement, creating cystic changes [34] . Although traditionally believed to be a polyclonal disorder, recent discovery of BRAF, NRAS, and mitogenactivated protein kinase mutations in a large proportion of PLCH patients suggests that PLCH is an inflammatory, metastasizing neoplasm driven by smoking-induced recruitment and proliferation of circulating histiocytes containing growthpromoting mutations [1 
PNEUMOTHORAX IN PULMONARY LANGERHANS CELL HISTIOCYTOSIS
Approximately 15-20% of patients with PLCH experience a pneumothorax (Table 2) [19,20, 39 & ,40] . Nearly 63% of those patients will have more than one pneumothorax, with ipsilateral recurrence rates approaching 56% [20] . Pneumothorax leads to the diagnosis of PLCH in approximately 11% of patients [20] . Simultaneous bilateral pneumothorax can occur and may be fatal [41] . In one study, patients with a history of pneumothorax averaged 2.3 total episodes [20] . Another study showed that prior to lung transplant, PLCH patients had averaged 3.4 pneumothorax episodes, with as many as 17 in one patient [42] . Pneumothorax of native lung has been reported posttransplant [42] . The age of diagnosis of PLCH is younger in those with pneumothorax, 27 versus 41.5 years old [20] . Pulmonary function tests and survival in PLCH do not seem to be affected by pneumothorax [20] .
MANAGEMENT
Due to high rate of recurrence, pleurodesis should be performed following the initial episode of pneumothorax rather than waiting for a recurrent event.
Mendez et al. [20] found a recurrence rate of 58% when managed conservatively, compared with 0% following surgical pleurodesis. Smoking status did not seem to impact pneumothorax rates [20] . Nevertheless, treatment of PLCH must involve smoking cessation, which can stabilize, improve, or even resolve the disease [43] . The role of steroids or chemotherapeutics such as cladribine on disease course is debated, and their effect on occurrence of pneumothorax is unclear [44] . With the recent discovery of underlying mitogen-activated protein kinase mutations in PLCH, there is potential for targeted treatment for these patients. The impact of targeted therapy on pneumothorax rates and overall disease course needs to be studied. 
Other neoplastic diffuse cystic lung diseases
Sarcomas commonly metastasize to the lungs, resulting in cystic changes and pneumothorax [45] . Prevalence of pneumothorax in sarcomas is 1.9%, varying by type, although higher rates (9.7%) are reported in patients on chemotherapy, likely due to necrosis of lesions following treatment [45, 46] . The most common sarcomas associated with pneumothorax are osteogenic sarcoma, angiosarcoma, and synovial cell sarcoma [45] . Pneumothorax recurrence rates are estimated to be 46% [45] . In one study, 15% of the pneumothoraces were discovered incidentally, and in a similar proportion of patients discovery of pneumothorax led to the diagnosis of their underlying malignancy [45] . Sarcoma-associated pneumothorax portends a very poor prognosis. More than 25% of patients die within a month, and the 1-year survival rate is about 20% [45] . Management of pneumothorax must be evaluated on a case-by-case basis based on overall prognosis and patient goals.
Other neoplastic processes such as ErdheimChester Disease [47] , pleuropulmonary blastoma [48, 49] , mesenchymal cystic hamartoma [50] , adenocarcinoma, and squamous cell carcinoma of the lung [51, 52] can rarely cause cystic lung changes and pneumothorax. , and disordered extracellular matrix remodeling involving matrix metalloproteinases [58] .
Birt-Hogg-Dubé syndrome
At least 80% of patients develop pulmonary cysts, which are typically thin-walled, irregular, elliptical-lentiform shaped in a basilar and subpleural distribution (Fig. 3) 
PNEUMOTHORAX IN BIRT-HOGG-DUBÉ SYNDROME
Patients with BHD have a 50-fold greater likelihood of pneumothorax as compared with age-matched ]; however, they have been reported in pediatric [67] as well as geriatric patients [68] . The presence of lung cysts and cyst burden including cyst number, size, and total cyst volume are associated with increased risk of pneumothorax [21] . Interestingly, there are reports of pneumothorax in patients without radiographically apparent cysts on computed tomography (CT) imaging [69] . Family history of pneumothorax is associated with higher risk of pneumothorax [63] ; however, smoking and the presence and/or severity of kidney tumors or fibrofolliculomas are not associated with an increased risk of pneumothorax [21, 60] . Pneumothorax recurrence rates in BHD are estimated to be 75-80% [21,22 & ]. Patients with BHD-associated pneumothorax experience an average of 3.6 total episodes of pneumothorax [22 & ].
MANAGEMENT
Given the high recurrence rate (>75%), pleurodesis should be performed following the first pneumothorax rather than waiting for a recurrence. Pleurodesis, although not perfect, can reduce the recurrence rates of ipsilateral pneumothorax in half (30% after pleurodesis as compared with >60% with conservative management) [22 & ]. Importantly, BHD does not typically result in progressive respiratory failure and thus concerns regarding pleural complications arising from pleurodesis during future lung transplantation are not applicable to this patient population [68] .
Marfan syndrome
Marfan syndrome is an autosomal dominant syndrome characterized by increased height, long limbs and digits, aortic root dilation, subluxation of the eyes, and apical pulmonary blebs [70] . It results from mutations in the gene encoding fibrillin-1, an important constituent of elastic fibers [71] . In addition to apical blebs, emphysematous and cystic changes have been reported [71, 72] . Pneumothoraces occur in 4-11% of patients [70] , which can be bilateral and recurrent [72] . Apical blebs or bullae predispose patients to pneumothorax, although pneumothoraces can occur in patients without these changes [71] . Some authors recommend definitive recurrence prevention with bullectomy or pleurodesis after first episode of pneumothorax [73] . In an effort to reduce the risk of pneumothorax, patients with Marfan syndrome are often advised to avoid breathing against resistance (e.g., playing brass instrument); scuba diving; high-altitude sports like skydiving; or flying in an unpressurized cabin [74] .
Other congenital or genetic diffuse cystic lung diseases
Ehlers-Danlos Type IV (vascular subtype) is an autosomal dominant inherited disorder of collagen characterized by thin skin; abnormal facial appearance; as well as vascular, intestinal, or uterine rupture [70, 75] . Pulmonary complications include cystic or bullous changes, as well as pneumothorax in up to 16% of patients [75, 76] . Congenital pulmonary airway malformation is the most common congenital lung lesion, which can lead to cystic changes and pneumothorax [77] . Bronchogenic cysts can also rarely cause pneumothorax [78] .
Pneumocystis jiroveci pneumonia
Pneumocystis jiroveci pneumonia (PJP) manifests as cystic lung changes in 10-34% of patients [79] . Cysts are usually bilateral, with a diffuse or upper lobe predominant distribution [79] . Cystic changes can occur in PJP associated with HIV or in other immunosuppressive states, and treatment of PJP can shrink or resolve cysts [1
Pneumothorax occurs in 4-12% of those with PJP [80] . The mechanism for pneumothorax involves necrotizing alveolitis with eventual replacement of subpleural parenchyma by necrotic cysts and pneumatoceles that can rupture leading to pneumothorax [81] . Cystic PJP is associated with a higher rate of spontaneous pneumothorax as compared with noncystic PJP [79] . Pneumothorax recurrence rates with conservative treatment are 35% [82] . Bilateral spontaneous pneumothoraces occur frequently in patients with HIV-related PJP [81, 83] . Patients who develop pneumothorax with PJP have a higher mortality than those with PJP without pneumothorax [79] .
Spontaneous pneumothorax in diffuse cystic lung diseases Cooley et al.
Patients with PJP and pneumothorax are prone to develop prolonged air leaks and treatment failure [81] . As such, early aggressive therapy with surgical referral and/or pleurodesis is recommended, along with medical management of HIV and PJP [80, 81] .
Other infectious diffuse cystic lung diseases
Recurrent respiratory papillomatosis [84] , paragonimiasis [85] , endemic fungal infections [1 & ,86], staphylococcus, and other Gram-negative infections can also result in formation of lung cysts and spontaneous pneumothorax [87, 88] .
Lymphoproliferative diffuse cystic lung diseases
Light chain deposition disease (LCDD) is a rare pulmonary lymphoproliferative disorder characterized by the accumulation of monoclonal, nonamyloid immunoglobulin deposits [89] . Patients with LCDD can have a primarily cystic imaging pattern that can mimic other common DCLDs such as LAM and PLCH, and also predispose patients to development of pneumothoraces [89] . Spontaneous pneumothorax has also been reported in DCLD secondary to Sjögren syndrome and lymphoid interstitial pneumonia [90, 91] .
RECENT ADVANCEMENTS
Recent publications regarding safety of atmospheric pressure changes, HRCT screening, and alternative techniques for management of pneumothorax have important implications for clinicians and patients.
Atmospheric pressure changes and risk of pneumothorax
Atmospheric pressure changes encountered during activities such air travel and diving may lead to cyst expansion and predispose patients with DCLDs to a higher risk of cyst rupture and development of pneumothorax. The risk of pneumothorax associated with air travel has been studied in LAM and, more recently, BHD. In LAM, rates of pneumothorax related to air travel are approximately 1.1-2.2% per flight [92, 93] . Importantly, some patients in these cohorts had symptoms consistent with a pneumothorax prior to boarding, thus the actual incidence of flight-related pneumothorax may be lower. Johannesma et al. recently conducted a retrospective analysis of 158 patients with BHD and found a flight-related pneumothorax rate of 0.63% per flight. However, in this study, a pneumothorax occurring within 30 days of the flight was considered as a flight-related pneumothorax, raising the concern for overestimation of the risk [65 & ]. In another recent analysis of 104 patients with BHD, the flight-related pneumothorax risk was estimated to be 0.12-0.27% per flight, with flight-related pneumothorax defined as a pneumothorax that occurred either during air travel or within 24 h of landing [22 & ]. The risk of pneumothorax was lower for patients with prior pleurodesis [22 & ]. The risk of flight-related pneumothorax is currently being evaluated for patients with PLCH (ClinicalTrials.gov, NCT03052101). In summary, it is safe for most patients with DCLDs to undertake air travel. Patients should be educated about the signs and symptoms of a pneumothorax and counseled not to fly and to seek medical evaluation in the presence of newonset/unexplained chest pain and/or dyspnea prior to boarding an airplane.
Limited disease-specific data are available regarding the safety of diving in patients with DCLDs. In a recent study involving 158 patients with BHD, the pneumothorax rate associated with diving was estimated to be 0.33% per session [65 & ]. However, given the paucity of disease-specific data, we recommend that patients with DCLDs avoid diving in accordance with the British Thoracic Society guidelines [81] .
Computed tomography screening for diffuse cystic lung diseases in patients presenting with a spontaneous pneumothorax Recent data suggest that BHD, LAM, and PLCH likely cause approximately 10% of apparent primary spontaneous pneumothoraces in the general population [61 & ,62,94,95 & ]. Current guidelines do not recommend screening CT for first-time pneumothoraces [10] . However, in a recent study, performing a screening HRCT to facilitate early diagnosis of LAM, BHD, or PLCH followed by pleurodesis was found to be cost-effective with a marginal costeffectiveness ratio of $1427 per quality-adjust lifeyear (QALY) gained, which is substantially lower than the commonly accepted threshold of $50 000/QALY [95 & ]. Based on these results, we recommend that all patients with an apparent primary spontaneous pneumothorax be screened with HRCT for the presence of underlying DCLDs.
Alternative techniques for pneumothorax management
Due to the persistent risk of pneumothorax recurrence after pleurodesis, as well as the risk of adhesions complicating future lung transplant, alternate management techniques are being explored. Total pleural covering (TPC), which involves wrapping the visceral pleura in a bioabsorbable mesh, has shown promise in preventing pneumothorax without severe impairment of lung function or formation of severe pleural adhesions [96 & ]. In a recent study involving 43 patients with LAM, TPC resulted in a pneumothorax recurrence rate (26%) that was comparable with traditional pleurodesis [15, 96 & ]. Successful use of TPC has also been reported in PLCH, BHD, bronchiolitis obliterans, and Ehlers-Danlos Syndrome [97, 98] . Blood patch pleurodesis, whereby a patient's own blood is instilled through an existing chest tube, has emerged as an effective option for treatment for pneumothorax with reported pneumothorax recurrence rates of 15.6-18.2% [99 & ]. The advantage of this technique is the almost complete absence of typical pleurodesis-associated side effects such as pain and fever [100] . The introduction of blood in an otherwise sterile cavity may, however, lead to an increased risk of infectious complications. These alternative techniques need to be better studied before widespread use can be recommended in patients with DCLDs.
CONCLUSION
DCLDs are increasingly being recognized as the cause of spontaneous pneumothoraces. Early diagnosis of DCLDs has management implications from both a pneumothorax as well as the underlying disease perspective. Performing an HRCT scan at the first episode of spontaneous pneumothorax to screen for underlying DCLDs can be cost-effective. In general, air travel is safe for most patients with DCLDs. Due to the high recurrence rate of pneumothoraces, pleurodesis should be considered following the sentinel event in patients with DCLDs. The impact of pneumothoraces on the natural history of these diseases, the efficacy of alternative techniques to reduce recurrence risk of pneumothoraces, and the impact of targeted pharmacologic therapy on future risk of pneumothoraces are some of the major unanswered questions that should be addressed in future studies. 
